Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raynaud's phenomenon

F M Wigley1

  • 1Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.

Current Opinion in Rheumatology
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Raynaud's phenomenon classification should be simplified to primary or secondary. Its complex pathophysiology involves vascular responses, with ongoing research into diagnostics and treatments like prostaglandins for severe cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea.

Annals of the rheumatic diseases·2009
Same author

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

The European respiratory journal·2009
Same author

Fatigue: an overlooked determinant of physical function in scleroderma.

Rheumatology (Oxford, England)·2008
Same author

Management of Severe Raynaud's Phenomenon.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

High-dose cyclophosphamide without stem cell rescue in scleroderma.

Annals of the rheumatic diseases·2007
Same author

A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).

Gut·2006
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Vascular Medicine
  • Rheumatology
  • Clinical Pathophysiology

Background:

  • Raynaud's phenomenon classification is complex, with inconsistent terminology like Raynaud's disease and syndrome.
  • Prevalence varies across populations and climates, indicating genetic and environmental factors.
  • Raynaud's phenomenon may represent a generalized vasospastic disorder, linked to conditions like migraine and variant angina.

Purpose of the Study:

  • To advocate for standardized classification of Raynaud's phenomenon as primary or secondary.
  • To review current understanding of Raynaud's pathophysiology.
  • To discuss advancements in diagnostics and treatment strategies.

Main Methods:

  • Literature review and synthesis of current research on Raynaud's phenomenon.

Related Experiment Videos

  • Analysis of diagnostic tools for digital circulation.
  • Evaluation of treatment outcomes for various interventions.

    • Main Results:

    • Standardized classification into primary and secondary Raynaud's phenomenon is recommended for clarity.
    • Pathophysiology is multifactorial, involving endothelial dysfunction, neuroreceptors, and local mediators.
    • Occupational causes remain a concern, while chemotherapy is a risk factor; surgery and prostaglandins show promise for severe cases.

    Conclusions:

    • Standardized classification is crucial for uniform reporting and patient management.
    • Understanding the complex pathophysiology aids in developing targeted therapies.
    • Continued research into diagnostics and treatments, including prostaglandins, is vital for managing Raynaud's phenomenon.